Aliases & Classifications for Phobic Disorder

MalaCards integrated aliases for Phobic Disorder:

Name: Phobic Disorder 12 14
Phobic Anxiety Disorder 69

Classifications:



Summaries for Phobic Disorder

Disease Ontology : 12 An anxiety disorder where fear and anxiety are triggered by a specific stimulus or situation.

MalaCards based summary : Phobic Disorder, also known as phobic anxiety disorder, is related to social phobia and phobia, specific. An important gene associated with Phobic Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Ethanol and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, ovary and skin, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Phobic Disorder

Diseases related to Phobic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Related Disease Score Top Affiliating Genes
1 social phobia 32.9 MAOA SLC6A4
2 phobia, specific 31.1 COMT MAOA NBAS
3 substance dependence 29.9 MAOA OPRK1 SLC6A4
4 agoraphobia 29.5 HTR1A MAOA OPRK1 PIR PTK7 RGS2
5 alcohol dependence 29.0 COMT HTR1A MAOA OPRK1 SLC6A4
6 anxiety 28.6 COMT HTR1A MAOA PTK7 SLC6A4
7 panic disorder 28.1 COMT HTR1A MAOA PTK7 RGS2 SLC6A4
8 schizoid personality disorder 10.4 HTR1A PIR
9 atypical depressive disorder 10.4 MAOA SLC6A4
10 obsessive-compulsive personality disorder 10.4 PIR SLC6A4
11 psychosexual disorder 10.3 HTR1A SLC6A4
12 pathological gambling 10.3 MAOA SLC6A4
13 periodic limb movement disorder 10.3 HTR1A SLC6A4
14 intermittent explosive disorder 10.2 HTR1A SLC6A4
15 dysthymic disorder 10.2 MAOA PIR SLC6A4
16 kleptomania 10.2 HTR1A MAOA SLC6A4
17 serotonin syndrome 10.2 HTR1A MAOA SLC6A4
18 endogenous depression 10.2 HTR1A MAOA SLC6A4
19 neonatal abstinence syndrome 10.2 COMT OPRK1
20 migraine without aura 10.1 HTR1A SLC6A4
21 dystonia 1, torsion, autosomal dominant 10.1 COMT MAOA
22 opiate dependence 10.1 OPRK1 SLC6A4
23 opioid addiction 10.1 COMT OPRK1
24 sudden infant death syndrome 10.0 HTR1A MAOA SLC6A4
25 oppositional defiant disorder 10.0 COMT MAOA SLC6A4
26 antisocial personality disorder 10.0 COMT MAOA SLC6A4
27 paranoid schizophrenia 10.0 COMT MAOA SLC6A4
28 early-onset schizophrenia 10.0 COMT MAOA SLC6A4
29 bulimia nervosa 1 10.0 COMT MAOA SLC6A4
30 premature ejaculation 10.0 COMT HTR1A SLC6A4
31 conduct disorder 10.0 COMT MAOA SLC6A4
32 dyspepsia 10.0 HTR1A SLC6A4
33 alexithymia 10.0 COMT HTR1A SLC6A4
34 substance abuse 10.0 COMT MAOA SLC6A4
35 post-traumatic stress disorder 10.0 COMT MAOA SLC6A4
36 bipolar i disorder 10.0 COMT HTR1A SLC6A4
37 separation anxiety disorder 10.0 NBAS PIR
38 psychotic disorder 10.0 COMT HTR1A SLC6A4
39 generalized anxiety disorder 9.9 HTR1A MAOA RGS2 SLC6A4
40 autism spectrum disorder 9.9 COMT MAOA SLC6A4
41 brunner syndrome 9.8 COMT HTR1A MAOA SLC6A4
42 postpartum depression 9.8 COMT HTR1A MAOA SLC6A4
43 borderline personality disorder 9.8 COMT HTR1A MAOA SLC6A4
44 mental depression 9.8 COMT HTR1A MAOA SLC6A4
45 cocaine dependence 9.8 OPRK1 SLC6A4
46 personality disorder 9.8 COMT HTR1A MAOA SLC6A4
47 aging 9.8
48 bulimia nervosa 2 9.8
49 chronic fatigue syndrome 9.8 COMT HTR1A MAOA SLC6A4
50 disease of mental health 9.8 COMT HTR1A MAOA SLC6A4

Graphical network of the top 20 diseases related to Phobic Disorder:



Diseases related to Phobic Disorder

Symptoms & Phenotypes for Phobic Disorder

MGI Mouse Phenotypes related to Phobic Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 HTR1A MAOA OPRK1 RGS2 SLC6A4 COMT
2 cardiovascular system MP:0005385 9.5 HTR1A MAOA PTK7 RGS2 SLC6A4 COMT
3 nervous system MP:0003631 9.23 MAOA OPRK1 PTK7 RGS2 SLC6A4 COMT

Drugs & Therapeutics for Phobic Disorder

Drugs for Phobic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2 64-17-5 702
2
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
3
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
4
Cycloserine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68-41-7 6234 401
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
7 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
8
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3 525-66-6 4946
9
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Phase 2 137-58-6 3676
10
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
11
Sertraline Approved Phase 4,Phase 3,Phase 2 79617-96-2 68617
12
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
13
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
14
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
15
Topiramate Approved Phase 4 97240-79-4 5284627
16
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
17
Acetylcholine Approved Phase 4 51-84-3 187
18
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
19 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
20
Serotonin Phase 4,Phase 2,Phase 3,Phase 1 50-67-9 5202
21 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Serotonin 5-HT1 Receptor Agonists Phase 4
24 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
26 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
27 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
29 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
31 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1
32 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3,Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Quetiapine Fumarate Phase 4,Phase 3,Phase 2,Early Phase 1 111974-72-2
44 Desvenlafaxine Succinate Phase 4 386750-22-7
45 Analgesics Phase 4,Phase 3,Phase 2,Early Phase 1
46 Adrenergic Agents Phase 4,Phase 3,Phase 2
47 Central Nervous System Stimulants Phase 4
48 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3
49 Serotonin Antagonists Phase 4,Phase 2
50 Adrenergic Antagonists Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 339)

# Name Status NCT ID Phase Drugs
1 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
2 RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
3 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
4 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
5 Nefazodone in the Treatment of Social Phobia Completed NCT00231348 Phase 4 Nefazodone
6 Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents Completed NCT01160588 Phase 4 Sertraline
7 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
8 Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder Completed NCT00872131 Phase 4 Sertraline
9 Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4 Gabitril
10 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
11 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
12 Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
13 Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
14 Escitalopram in Patients With Social Anxiety Disorder Completed NCT00902226 Phase 4 Escitalopram
15 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
16 Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
17 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
18 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
19 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
20 Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP) Recruiting NCT00182455 Phase 4 Topiramate;Placebo
21 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
22 Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet H4™) in Healthy Young Adults Active, not recruiting NCT03150537 Phase 4
23 Brief Intervention to Reduce Fear of Public Speaking Active, not recruiting NCT02790736 Phase 4 propranolol;placebo
24 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Active, not recruiting NCT02294305 Phase 4 Vortioxetine;Placebo
25 Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Terminated NCT01623583 Phase 4
26 A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder Terminated NCT03078270 Phase 4 botulinum toxin A
27 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
28 Study of Escitalopram in the Treatment of Specific Phobia Completed NCT00121069 Phase 2, Phase 3 Escitalopram
29 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
30 Residential Cognitive and Interpersonal Therapy for Social Phobia Completed NCT00326430 Phase 2, Phase 3
31 A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Completed NCT00564967 Phase 3
32 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
33 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
34 Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Completed NCT00958880 Phase 3 Yohimbine Hydrochloride;Sugar Pill
35 Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Completed NCT00734422 Phase 2, Phase 3
36 Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Completed NCT02007694 Phase 2, Phase 3
37 Long-term Study Of Paroxetine in Women and Men Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
38 D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia Completed NCT01102803 Phase 3 D-Cycloserine;Placebo
39 Social Anxiety Disorder Study Of Paroxetine Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
40 Flushing in Social Anxiety Disorder on Seroquel Completed NCT00773162 Phase 3 Seroquel;Sugar Pill
41 Child and Adolescent Anxiety Disorders (CAMS) Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
42 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder Completed NCT00260533 Phase 2, Phase 3 atomoxetine;placebo
43 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder Completed NCT00074802 Phase 3 Paroxetine
44 Quetiapine in Social Anxiety Disorder Completed NCT00215254 Phase 2, Phase 3 quetiapine
45 Treatment for Anxiety in Children Completed NCT00000389 Phase 3 Fluvoxamine
46 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
47 St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD) Completed NCT00118833 Phase 2, Phase 3 Hypericum perforatum (St. John's wort)
48 Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) Completed NCT02622958 Phase 3 PH94B
49 A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder Completed NCT01654510 Phase 2, Phase 3
50 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed NCT00114127 Phase 3 Duloxetine;Duloxetine;Placebo

Search NIH Clinical Center for Phobic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Phobic Disorder

Anatomical Context for Phobic Disorder

MalaCards organs/tissues related to Phobic Disorder:

38
Brain, Ovary, Skin, Eye

Publications for Phobic Disorder

Articles related to Phobic Disorder:

(show all 14)
# Title Authors Year
1
Choking Phobia : An Uncommon Phobic Disorder, Treated with Behavior Therapy : A Case Report and Review of the Literature. ( 28638212 )
2016
2
Validation of the diagnoses of panic disorder and phobic disorders in the US National Comorbidity Survey Replication Adolescent (NCS-A) supplement. ( 21495110 )
2011
3
Genetic association between BDNF gene polymorphisms and phobic disorders: a case-control study among mainland Han Chinese. ( 21295349 )
2011
4
The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. ( 15897725 )
2005
5
Temporal relationship between the age of onset of phobic disorders and development of substance dependence in adolescent psychiatric patients. ( 15283954 )
2004
6
A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. ( 11509185 )
2001
7
Social and personal resources and the prevalence of phobic disorder in a community population. ( 10883724 )
2000
8
The longitudinal study of phobic disorder in a community sample from early to late adolescence. ( 11018436 )
2000
9
Phobic disorder, psychotherapy, and risk-taking: an economic perspective. ( 10180917 )
1998
10
Frequency of phobic disorder in a community sample of young adolescents. ( 7559315 )
1995
11
Role of thymic hormones in neuroimmunomodulation. Their use in patients with phobic disorders. ( 1776534 )
1991
12
Administration of thymopentin to patients with phobic disorders improves depressed phagocytic functions. ( 2092042 )
1990
13
Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. ( 2651489 )
1989
14
Is anorexia nervosa a phobic disorder? A psychophysiological enquiry. ( 7417632 )
1980

Variations for Phobic Disorder

Copy number variations for Phobic Disorder from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 94765 15 70400000 76100000 Copy number LOXL1 phobic disorder

Expression for Phobic Disorder

Search GEO for disease gene expression data for Phobic Disorder.

Pathways for Phobic Disorder

GO Terms for Phobic Disorder

Cellular components related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.02 GLRB HTR1A OPRK1 PTK7 SLC6A4

Biological processes related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of sensory perception of pain GO:0051930 9.37 COMT OPRK1
2 vasoconstriction GO:0042310 9.32 HTR1A SLC6A4
3 behavior GO:0007610 9.26 HTR1A OPRK1
4 neurotransmitter catabolic process GO:0042135 9.16 COMT MAOA
5 catecholamine metabolic process GO:0006584 8.96 COMT MAOA
6 dopamine catabolic process GO:0042420 8.62 COMT MAOA

Sources for Phobic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....